Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
109.9 USD | +0.61% | -0.58% | -10.62% |
Financials (USD)
Sales 2024 * | 4.09B | Sales 2025 * | 4.39B | Capitalization | 6.85B |
---|---|---|---|---|---|
Net income 2024 * | 475M | Net income 2025 * | 648M | EV / Sales 2024 * | 2.41 x |
Net Debt 2024 * | 3B | Net Debt 2025 * | 1.61B | EV / Sales 2025 * | 1.93 x |
P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
11.2
x | Employees | 2,800 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.18% |
Latest transcript on Jazz Pharmaceuticals plc
1 day | +0.61% | ||
1 week | -0.58% | ||
Current month | -8.70% | ||
1 month | -12.05% | ||
3 months | -5.66% | ||
6 months | -16.73% | ||
Current year | -10.62% |
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Renée Galá
PSD | President | 52 | 20-03-15 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 19-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-12 |
Patrick Enright
BRD | Director/Board Member | 62 | 08-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.34% | 13 M€ | -.--% | ||
14.47% | 215 M€ | +13.63% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 109.9 | +0.61% | 756,641 |
24-04-18 | 109.3 | +2.03% | 564,463 |
24-04-17 | 107.1 | -1.65% | 592,713 |
24-04-16 | 108.9 | -1.81% | 545,622 |
24-04-15 | 110.9 | +0.30% | 603,233 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.62% | 6.81B | |
+24.60% | 672B | |
+24.08% | 550B | |
-5.63% | 351B | |
+15.37% | 317B | |
+7.38% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-9.69% | 144B | |
-6.63% | 141B |
- Stock Market
- Equities
- JAZZ Stock